FTX and myeloid sarcoma: As shown in Fig. 5, lncRNA Ftx demonstrated limited diagnostic utility for distinguishing between healthy controls and MS (p = 0.4585, AUC = 0.5329), SPMS (p = 0.2690, AUC = 0.5565), and RRMS (p = 0.8484, AUC = 0.5097).